D2C7-IT

Phase 1Small molecule

DDarell Bigner

D2C7-IT is one of 76 small molecule programs targeting Malignant Glioma. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Malignant GliomaCompleted

Newly DiagnosedRecruiting

Malignant GliomaPhase 1

Completed

Newly DiagnosedPreclinical

Recruiting

Competition

Competitive Landscape

76 competitors in Newly Diagnosed

#DrugCompanyPhaseTrials

Venclexta

AbbVie

Phase 3

15 2

Cytosar

Teva

Phase 3

14 3

Rituxan

Roche

Phase 3

11 4

Oncovin

Eli Lilly

Phase 3

7 5

Adriamycin

Pfizer

Phase 3

6 6

Darzalex

Johnson & Johnson

Phase 3

4 7

Decadron

AAspen Global Incorporated

Phase 3

14 8

Oncovin

Eli Lilly

Phase 3

3 9

Vanflyta

Daiichi Sankyo

Phase 3

3 10

Cytoxan

BBaxter Healthcare Corporation

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 1Recruiting

Malignant Glioma

NCT04547777

Q4 2028

PreclinicalRecruiting

Glioblastoma Multiforme

NCT05734560

Q1 2030

Phase 1Recruiting

Recurrent Glioblastoma IDH Wildtype

NCT06455605

Clinical

Trials by Indication[1]

Malignant Glioma3 trials

Phase 1 Trial of D2C7-IT in Combination With 2141-V11 for Recurrent Malignant Glioma

Recruiting·DDarell Bigner·Phase 1·NCT04547777·90 enrolled

Phase I Single-Center, Dose Escalation Study of D2C7-IT Administered Intratumorally Via Convection-Enhanced Delivery for Adult Patients With Recurrent Malignant Glioma

Completed·DDarell Bigner·Phase 1·NCT02303678·81 enrolled

A Phase 1 Trial of D2C7-IT in Combination With Atezolizumab in Recurrent WHO Grade IV Malignant Glioma

Completed·DDarell Bigner·Phase 1·NCT04160494·14 enrolled

Recurrent Glioblastoma IDH Wildtype1 trial

Clinical Trial of D2C7-IT + 2141-V11 Combination Immunotherapy Administered Via Convection Enhanced Delivery in Non-enhancing Tumor Post-resection of Recurrent Glioblastoma, Followed by Cervical Perilymphatic Subcutaneous Injections of 2141-V11

Recruiting·DDarell Bigner·Phase 1·NCT06455605·46 enrolled

Glioblastoma Multiforme1 trial

Delivery of D2C7-IT and 2141-V11 Combination Immunotherapy in Residual Disease for Adult Patients With Newly Diagnosed MGMT Unmethylated Glioblastoma and Perilymphatic Subcutaneous Injections of 2141-V11

Recruiting·DDarell Bigner·Preclinical·NCT05734560·50 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for D2C7-IT. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — D2C7-IT compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for D2C7-IT. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Darell Bigner company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: DDarell Bigner

D2C7-IT

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q4 2028

Q1 2030

Trials by Indication[1]

Malignant Glioma3 trials

Recurrent Glioblastoma IDH Wildtype1 trial

Glioblastoma Multiforme1 trial

References

Drug Info

Quick Facts

Related News